Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2019-04-30 Report Publication Anno…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 1% confidence The document is a press release titled "ABIVAX : Mise à disposition du Document de Référence 2019" (ABIVAX: Availability of the 2019 Reference Document). It explicitly states that the 2019 Reference Document (which contains the 2018 annual financial report and governance report) has been made available to the AMF (Autorité des Marchés Financiers). Since the document itself is an announcement about the publication of a report, and not the full report, it fits the definition of a Report Publication Announcement (RPA). The document length (2247 chars) is short, supporting the RPA classification over the full report (10-K or AR).
2019-04-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces clinical trial progress, regulatory authorizations (Phase 2b Ulcerative Colitis trial authorization in Canada), scheduled future events (FPI dates, DDW presentation), and provides updates on financial outlook ("build strong shareholder value"). This structure—a formal announcement of operational and clinical milestones, often released outside of mandatory periodic filings—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses heavily on operational updates and clinical progress rather than just summarizing period-end financial results (which would be ER) or being a comprehensive report (like 10-K or IR), and it is not a transcript, proxy, or management discussion, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less focused on performance updates. Given the context of providing updates on clinical development plans and upcoming data presentations, ER is the most appropriate fit for a company update of this nature, even if it's not strictly quarterly results. However, since it is a general announcement of progress and not explicitly tied to a specific reporting period's financial results summary, and it contains significant operational/clinical news, it could also be classified as a general Regulatory Filing (RNS) if ER is reserved strictly for financial summaries. Reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is more about clinical milestones and future plans than past financial results highlights. Therefore, RNS (Regulatory Filings - general regulatory announcements and fallback) is a safer classification for a broad operational/clinical update press release that doesn't fit the specific financial report categories.
2019-04-30 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Communiqué de Presse" (Press Release) and is dated April 30, 2019. It announces several key operational updates, including regulatory authorizations for a Phase 2b clinical trial, expected patient enrollment timelines for Phase 2a trials in other indications (rheumatoid arthritis and Crohn's disease), and upcoming data presentations at a medical conference (DDW). This format—a brief announcement summarizing recent corporate and clinical progress, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on clinical trial progress and regulatory milestones rather than comprehensive financial results (which would suggest 10-K or IR), and it is a direct announcement rather than a link to a larger report (ruling out RPA/RNS based on content depth), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede formal quarterly financial reporting, or serve as major operational updates. However, given the strong focus on clinical trial updates and pipeline progress, it could also be considered an Investor Presentation (IP) if it were a slide deck, but as a press release detailing operational milestones, ER is a strong fit for a general operational/results update announcement. Since it is not a full financial report (10-K/IR) but an announcement of progress, ER is the best fit among the options provided for a major corporate update release.
2019-04-30 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references compliance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, providing a table detailing the number of shares and voting rights as of a specific date (28/02/2019). This structure is characteristic of mandatory regulatory disclosures in France concerning share capital structure and voting power changes. This type of filing, which reports changes in the total number of shares and voting rights, is most closely aligned with notifications regarding capital structure or major shareholding changes. Since it is a specific regulatory disclosure about the capital structure (shares and voting rights) rather than a general announcement of a transaction (POS) or a threshold crossing (MRQ), and given the options, it relates most closely to capital structure updates. However, none of the codes perfectly match a 'Total Voting Rights' disclosure. The closest fit among the provided options that deals with capital structure and share counts is 'Share Issue/Capital Change' (SHA), although this document is specifically a periodic disclosure of the total count. Given the context of French regulation (AMF) and the content focusing purely on the total number of shares and voting rights, it is a mandatory disclosure related to the capital base. If a more specific code for 'Total Voting Rights Disclosure' existed, it would be used. In its absence, SHA (Share Issue/Capital Change) is the most relevant category dealing with the fundamental share count, or potentially RNS as a general regulatory filing. Since it is a structured, periodic report on the capital base, SHA is a stronger fit than the general RNS fallback, as it directly concerns the 'capital' aspect.
2019-03-18 French
Abivax veroffentlicht Jahresfinanzergebnis 2018 und gibt Update zur Unternehmensentwicklung (News mit Zusatzmaterial)
Earnings Release Classification · 1% confidence The document is titled "Abivax veröffentlicht Jahresfinanzergebnis 2018 und gibt Update zur Unternehmensentwicklung" (Abivax publishes Annual Financial Results 2018 and provides an update on corporate development). It contains detailed financial tables for the year ended December 31, 2018, including P&L items (Operativer Umsatz, Operativer Aufwand, Jahresfehlbetrag) and Balance Sheet items (Bilanzsumme, Kapital der Anteilseigner). The text explicitly mentions that the financial results for the fiscal year 2018 are being published and that the annual financial statements were approved by the supervisory board. Although it also contains operational updates (pipeline progress), the core focus and structure revolve around the full-year financial performance review. This strongly indicates an Annual Report or a document closely associated with it, but since it is presented as a news release detailing the full-year results, it aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed Earnings Release/Interim Report. Given the inclusion of full comparative financial statements (P&L and Balance Sheet) for the entire fiscal year (2018 vs 2017), it is more comprehensive than a typical Earnings Release (ER) which usually provides only highlights. However, the text states: "Der Jahresabschluss für das Geschäftsjahr 2018 wurde am 12. März 2019 vom Aufsichtsrat des Unternehmens genehmigt und von den externen Wirtschaftsprüfern des Unternehmens geprüft. Der Abschlussbericht befindet sich in Vorbereitung." This suggests the formal 10-K filing might be pending, and this document serves as the comprehensive release of the audited annual figures. In the context of the provided definitions, a comprehensive report covering full-year activity and financial performance, even if released via a news wire, is best classified as an Annual Report (10-K) if it contains the full financial details, or potentially an Interim Report (IR) if it were for a shorter period. Since it covers the full fiscal year and includes detailed financials, 10-K is the most appropriate fit among the options for a full-year financial disclosure, even if it's a press release format. Revisiting the definitions: 10-K is for the 'Official yearly report'. IR is for 'Interim / Quarterly Report'. Since this covers the full year (Jahresfinanzergebnis 2018), 10-K is the intended category for the full annual disclosure, despite the format being a news release announcing the results. FY 2018
2019-03-14 German
Abivax SA (ABVX-FR): ABX464: sustained safety and benefit in inflammatory bowel
Investor Presentation Classification · 1% confidence The document is an analysis report published by 'goetzpartners securities Limited' concerning Abivax SA, detailing drug trial data, providing a recommendation ('OUTPERFORM'), and setting a target price. This content structure—analysis, recommendation, target price, and detailed clinical/market commentary—is characteristic of an Investor Presentation (IP) or Equity Research Report. Since 'Investor Presentation' (IP) is an available category for detailed investor-focused materials, and this document functions as a detailed research report intended for professional investors, IP is the most appropriate classification over a general 'Regulatory Filing' (RNS). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a management discussion (MDA), but rather an independent analysis.
2019-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.